Moody Aldrich Partners LLC Sells 51,872 Shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX)

Moody Aldrich Partners LLC lowered its stake in Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Free Report) by 43.5% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 67,415 shares of the company's stock after selling 51,872 shares during the quarter. Moody Aldrich Partners LLC owned about 0.11% of Protagonist Therapeutics worth $2,602,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently bought and sold shares of PTGX. RTW Investments LP boosted its holdings in shares of Protagonist Therapeutics by 2.6% in the third quarter. RTW Investments LP now owns 5,426,112 shares of the company's stock valued at $244,175,000 after acquiring an additional 139,708 shares in the last quarter. State Street Corp boosted its stake in Protagonist Therapeutics by 52.9% during the 3rd quarter. State Street Corp now owns 3,183,542 shares of the company's stock valued at $143,259,000 after purchasing an additional 1,101,218 shares in the last quarter. Pacer Advisors Inc. increased its position in shares of Protagonist Therapeutics by 8.2% during the 4th quarter. Pacer Advisors Inc. now owns 1,876,466 shares of the company's stock valued at $72,432,000 after purchasing an additional 142,376 shares during the period. Geode Capital Management LLC raised its stake in shares of Protagonist Therapeutics by 0.3% in the 3rd quarter. Geode Capital Management LLC now owns 1,374,697 shares of the company's stock worth $61,873,000 after buying an additional 3,528 shares in the last quarter. Finally, Millennium Management LLC boosted its stake in Protagonist Therapeutics by 2,135.6% during the second quarter. Millennium Management LLC now owns 958,283 shares of the company's stock valued at $33,205,000 after buying an additional 915,418 shares in the last quarter. Institutional investors own 98.63% of the company's stock.

Insider Activity at Protagonist Therapeutics

In other Protagonist Therapeutics news, insider Arturo Md Molina sold 26,000 shares of the company's stock in a transaction dated Wednesday, November 27th. The shares were sold at an average price of $44.70, for a total transaction of $1,162,200.00. Following the completion of the sale, the insider now directly owns 46,444 shares in the company, valued at $2,076,046.80. This represents a 35.89 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Suneel Gupta sold 103,437 shares of Protagonist Therapeutics stock in a transaction dated Monday, November 25th. The stock was sold at an average price of $46.04, for a total value of $4,762,239.48. Following the completion of the transaction, the insider now owns 256,174 shares in the company, valued at $11,794,250.96. The trade was a 28.76 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 209,863 shares of company stock valued at $9,689,847. Insiders own 5.40% of the company's stock.

Protagonist Therapeutics Stock Up 1.3 %

Shares of PTGX traded up $0.49 during midday trading on Wednesday, reaching $38.48. 112,292 shares of the stock were exchanged, compared to its average volume of 551,333. The company has a market cap of $2.29 billion, a price-to-earnings ratio of 14.45 and a beta of 2.23. Protagonist Therapeutics, Inc. has a 12-month low of $24.22 and a 12-month high of $48.89. The firm has a 50 day simple moving average of $39.95 and a 200-day simple moving average of $41.86.

Protagonist Therapeutics (NASDAQ:PTGX - Get Free Report) last issued its quarterly earnings data on Thursday, November 7th. The company reported ($0.54) earnings per share for the quarter, beating the consensus estimate of ($0.59) by $0.05. The firm had revenue of $4.68 million for the quarter, compared to analyst estimates of $4.50 million. Protagonist Therapeutics had a net margin of 52.76% and a return on equity of 34.68%. Research analysts expect that Protagonist Therapeutics, Inc. will post 2.28 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several brokerages have recently issued reports on PTGX. HC Wainwright reaffirmed a "buy" rating and issued a $50.00 price objective on shares of Protagonist Therapeutics in a research note on Tuesday, December 10th. StockNews.com lowered shares of Protagonist Therapeutics from a "buy" rating to a "hold" rating in a research report on Tuesday, December 10th. BMO Capital Markets started coverage on Protagonist Therapeutics in a research report on Friday, December 6th. They set an "outperform" rating and a $62.00 price objective for the company. Wedbush reissued an "outperform" rating and set a $58.00 price objective on shares of Protagonist Therapeutics in a research note on Tuesday, November 19th. Finally, The Goldman Sachs Group began coverage on Protagonist Therapeutics in a research report on Friday, December 6th. They set a "neutral" rating and a $47.00 target price on the stock. Two analysts have rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, Protagonist Therapeutics presently has a consensus rating of "Moderate Buy" and an average price target of $53.78.

Protagonist Therapeutics Profile

Protagonist Therapeutics, Inc, a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis.